Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	4.79M 0 4.19M 3.87M 3.58M 6.74M 460M 6.86M 46.19M 18.12M 225M 18.01M 17.61M 776M	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	4.79M 0 4.19M 3.87M 3.58M 6.74M 460M 6.86M 46.19M 18.12M 225M 18.01M 17.61M 776M	EV / Sales 2026 *	3.23x	EV / Sales 2027 *	1.84x
Free-Float	82.9%	Yield 2026 *	-	Yield 2027 *	-

07-10	L.I.A. Pure Capital Sends Letter to Evogene	CI
07-08	Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	CI
06-24	Evogene Ltd. And Google Cloud Announces Major Milestone In Collaboration Advancing ChemPass AI Toward Autonomous Small Molecule Discovery And Optimization	CI
06-02	Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with Nivolumab	CI
05-20	Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-20	Evogene Ltd., Q1 2026 Earnings Call, May 20, 2026
05-20	Evogene Ltd files for offering of 2.45 million ordinary shares by selling shareholder SEC filing	RE
05-18	Evogene Ltd.'S Subsidiary Ag Plenus Ltd. and Bayer Ag to Discontinue Their Herbicide Development Project	CI
04-24	Evogene's Casterra unit eyes castor crop growth in Brazil	RE
04-02	Evogene reports receipt of Nasdaq minimum bid price notification	RE
04-02	Evogene Gets Nasdaq Minimum Bid Price Notification	MT
03-05	Evogene Ltd., Q4 2025 Earnings Call, Mar 05, 2026
03-05	Evogene Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

02/10/23	Alliance Global Starts Evogene at Buy With $1.85 Price Target	MT
18/08/23	Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	MT
29/07/21	EVOGENE : Aegis Capital Starts Evogene at Buy	MT
01/12/20	EVOGENE : Cantor Fitzgerald Starts Evogene at Overweight With $9 Price Target	MT

07-08	Evogene : and Tel Aviv University’s Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	PU
06-02	Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica	PR
05-20	Evogene : Q1 2026 Consolidated Financial Statements	PU
05-20	Evogene: Q1 Earnings Snapshot	AQ
05-20	Evogene Reports First Quarter 2026 Financial Results	PR

Manager	Title	Age	Since
Ofer Haviv CEO	Chief Executive Officer	60	30/11/2004
Gabi Tarcic PRN	Corporate Officer/Principal	-	-
Polina Ravzin PRN	Corporate Officer/Principal	-	31/12/2021

Evogene Ltd Share Price TEL AVIV STOCK EXCHANGE

Stocks

IL0011050551

Biotechnology & Medical Research

Valuation: Evogene Ltd

Latest news : Evogene Ltd

Last Transcript: Evogene Ltd

Analysts' recommendations: Evogene Ltd

Press Releases: Evogene Ltd

News in other languages: Evogene Ltd

Quotes and Performance

Managers and Directors: Evogene Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Dan Falk BRD	Director/Board Member	81	16/11/2021
Sarit Firon CHM	Chairman	60	31/05/2021
Leon Recanati BRD	Director/Board Member	77	02/06/2010

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVOGENE LTD	-0.43%	-5.52%	-	-	5.36M
LONZA GROUP AG	-1.05%	+1.39%	+3.15%	+6.98%	50.61B
REVOLUTION MEDICINES, INC.	+0.55%	-2.88%	+382.07%	+593.81%	39.11B
IQVIA HOLDINGS INC.	+0.13%	-0.19%	+29.79%	-6.00%	34.64B
BEONE MEDICINES AG	+0.86%	-0.78%	+21.58%	+56.15%	33.79B
CELLTRION, INC.	-1.31%	-3.03%	+2.51%	+25.24%	26.89B
ASCENDIS PHARMA A/S	+0.13%	-0.52%	-	-	16.47B
MEDPACE HOLDINGS, INC.	+1.13%	-1.85%	+67.36%	+120.46%	15.14B
EUROFINS SCIENTIFIC SE	-0.72%	+0.12%	+14.69%	+16.95%	13.85B
ICON PUBLIC LIMITED COMPANY	+1.13%	-0.44%	+12.34%	-31.79%	12.72B
Average	+0.04%	-1.54%	+66.69%	+97.72%	27.02B
Weighted average by Cap.	-0.04%	-1.14%	+80.75%	+121.71%

	2026 *	2027 *
Net sales	1.48M 0 1.3M 1.2M 1.11M 2.09M 143M 2.12M 14.3M 5.61M 69.8M 5.57M 5.45M 240M	2.6M 0 2.27M 2.1M 1.94M 3.65M 250M 3.72M 25.05M 9.83M 122M 9.77M 9.55M 421M
Net income	-16.69M -0 -14.58M -13.48M -12.45M -23.45M -1.6B -23.88M -161M -63.08M -785M -62.68M -61.29M -2.7B	-13.92M -0 -12.16M -11.24M -10.39M -19.56M -1.34B -19.91M -134M -52.6M -654M -52.27M -51.11M -2.25B
Net Debt	-	-